| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-29 | Boudreau Helen M | director | Award | 81,000 | $5.95 | $482K |
| 2026-05-15 | Stout Stephen | officer | Award | 12,805 | $1.08 | $14K |
| 2026-05-15 | Stout Stephen | officer | Option exercise | 12,805 | $1.08 | $14K |
| Filed | Form | Filer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-10-27 | SCHEDULE 13G | BlackRock, Inc. | — | — | view → |
| 2026-07-17 | SCHEDULE 13D/A | Redmile Group, LLC | 9.90% | 10,019,421 | view → |
| 2026-06-15 | SCHEDULE 13D/A | ORBIMED ADVISORS LLC | — | 9,021,127 | view → |
| 2026-06-11 | SCHEDULE 13D/A | Redmile Group, LLC | 9.90% | 9,819,084 | view → |
| Filed | Form | Issuer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-10-23 | SCHEDULE 13G | TCGX Acquisition Corp. II | — | — | view → |
| 2026-10-23 | SCHEDULE 13G | Alector, Inc. | — | — | view → |
| 2026-10-21 | SCHEDULE 13G | Frazier Life Sciences Acquisition Corp. II | — | — | view → |
| 2026-09-02 | SCHEDULE 13G | JATT III Acquisition Corp | — | — | view → |
| 2026-05-29 | SCHEDULE 13G | Avalo Therapeutics, Inc. AVTX | — | — | view → |
| 2025-02-19 | SCHEDULE | DYNAVAX TECHNOLOGIES CORP | 13.50% | 17,791,486 | view → |
Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.
See pricing →